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Abstract
Background: A growing population of patients lives with severe coronary artery disease not amenable to coronary
revascularization and with refractory angina despite optimal medical therapy. Percutaneous reduction of the
coronary sinus is an emerging treatment for myocardial ischemia that increases coronary sinus pressure to promote
a transcollateral redistribution of coronary artery in-flow from nonischemic to ischemic subendocardial territories. A
first-in-man study has demonstrated that the percutaneous reduction of the coronary sinus can be performed safely
in such patients. The COSIRA trial seeks to assess whether a percutaneous reduction of the coronary sinus can
improve the symptoms of refractory angina in patients with limited revascularization options.
Methods/Design: The COSIRA trial is a phase II double-blind, sham-controlled, randomized parallel trial comparing
the percutaneously implanted coronary sinus Reducer (Neovasc Inc, Richmond, BC, Canada) to a sham implantation
in 124 patients enrolled in Canada, Belgium, England, Scotland, Sweden and Denmark. All patients need to have
stable Canadian Cardiovascular Society (CCS) class III or IV angina despite optimal medical therapy, with evidence of
reversible ischemia related to disease in the left coronary artery, and a left ventricular ejection fraction >25%.
Participants experiencing an improvement in their angina ≥2 CCS classes six months after the randomization will
meet the primary efficacy endpoint. The secondary objective of this trial is to test whether coronary sinus Reducer
implantation will improve left ventricular ischemia, as measured by the improvement in dobutamine
echocardiogram wall motion score index and in time to 1 mm ST-segment depression from baseline to six-month
post-implantation.
Discussion: Based on previous observations, the COSIRA is expected to provide a significant positive result or an
informative null result upon which rational development decisions can be based. Patient safety is a central concern
and extensive monitoring should allow an appropriate investigation of the safety related to the coronary sinus
Reducer.
Trial registration: ClinicalTrials.gov identifier - NCT01205893.
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In patients with stable coronary artery disease (CAD), a
successful treatment is defined as a complete, or nearly
complete, elimination of anginal chest pain with improved
functional class and a return to normal activities [1]. This
goal cannot be achieved in a growing population of
patients [2,3] with advanced CAD having no option for
further revascularization either by percutaneous coronary
intervention (PCI) or by coronary artery bypass graft
(CABG) surgery. These ‘no option’ patients remain se-
verely disabled by chronic refractory angina pectoris,
despite optimal medical therapy. The worldwide preva-
lence of ‘no option’ patients with refractory angina is
growing and new therapeutic options are required [4].
Experimental evidence revealed that in the setting of a
significant epicardial coronary artery stenosis, increased
coronary sinus (CS) pressure can lead to redistribution
of blood flow from nonischemic to ischemic myocardial
territories [5]. In the 1950s, partial ligation of the CS
was hypothesized to force oxygenized arterial blood into
underperfused myocardial segments
2. Historically, the
partial ligation of the CS by surgery has been associated
with a reduction in mortality (13% vs. 30% for nonoperated
subjects) [6,7], and an improvement of angina [6-10]. The
success of CABG decreased interest in surgical ligation of
C Sb u tt h ec u r r e n tr i s ei np a t i e nts with refractory angina
creates an opportunity to reconsider this approach.
In the healthy heart, selective sympathetically mediated
constriction of subepicardial vessels during exercise
maintains adequate subendocardial perfusion and a proper
myocardial function. In the presence of an epicardial
coronary artery stenosis, the constriction of subepicardial
vessels becomes dysfunctional and is unable to compen-
sate for the lack of oxygenated blood [11]. In patients
with ischemic cardiomyopathy, the perfusion of the
subendocardial layers may be further compromised when-
ever the left ventricle end-diastolic pressure is elevated
[12]. In the setting of advanced CAD, elevated CS pressure
could ameliorate subendocardial ischemia by normalizing
the subendocardial to subepicardial blood flow ratio and
lead to redistribution of collateral blood flow from
nonischemic to ischemic territories of the myocardium.
Percutaneous CS reduction
Today, the concept of percutaneous CS narrowing is
emerging as a possible treatment option. The coronary
sinus Reducer (Neovasc Inc, Richmond, Canada) is a
percutaneous, endoluminal, hourglass-shaped, balloon-
expandable stainless steel device that is designed to
be implanted in the CS to create a controlled local
narrowing, which modifies myocardial blood flow and
coronary sinus pressure (Figure 1a). By increasing
the CS pressure, the Neovasc Reducer
™ System is
thought to favor redistribution of oxygenated coronary
artery blood flow toward underperfused ischemic
subendocardium. The Reducer is made of surgical grade
316LVM stainless steel, laser cut into a prespecified geo-
metric pattern with flexible longitudinal struts and no
welding points. The Reducer is available in one single
model designed to fit a range of anatomies. Its final
expanded diameter is dependent on the inflation pressure
of the semi-compliant balloon. The Neovasc Reducer
™ Bal-
loon Catheter (Figure 1b) is an over-the-wire catheter with
a unique hourglass-shaped balloon to conform to the
tapering typically encountered in the CS.
In 2007, Banai et al. reported first-in-man experience
with the Reducer in 15 unrevascularizable patients [13]. In
12 patients, the Reducer was associated with a significant
improvement in angina class (Canadian Cardiovascular
Society (CCS) scores 3.07 at baseline vs. 1.64 at follow-up,
P <0.0001). The symptom relief correlated with objective
myocardial ischemia reduction measured with thallium
single-photon emission computed tomography (SPECT)
and stress echocardiography. At three-year follow-up, no
patient experienced death or myocardial infarction attri-
butable to the device. The computed tomography (CT)
angiography revealed patency of all Reducers with no evi-
dence of device migration. Overall, the improvement in
angina score was maintained [14].
The supportive experimental evidence combined with
first-in-man results led to the Coronary Sinus Reducer
for Treatment of Refractory Angina (COSIRA) trial,
which is designed to provide an alternative treatment
strategy to improve symptoms of refractory angina in no
option patients with reversible myocardial ischemia, sec-
ondary to CAD.
Methods/Design
Study objectives
COSIRA is a prospective, multicenter, randomized, double-
blind, sham-controlled clinical trial of the safety and effect-
iveness of the CS Reducer. The primary endpoint of this trial
is improvement in angina symptoms, measured with the
CCS classification, in patients with limited revascularization
option despite severe refractory angina. This study also aims
to demonstrate that the Reducer implantation can be
performed safely with a minimally invasive percutaneous
approach. Other secondary objectives of this trial will test
whether CS Reducer implantation will improve myocardial
ischemia, as measured by a sestamibi (MIBI) SPECT stress
test, the dobutamine echocardiogram wall motion score
index,the Seattle Angina Questionnaire (SAQ) and thetime
to 1 mmST-segmentdepression.
Study population and patient selection
One hundred and twenty-four patients are currently
being enrolled at up to 14 sites located in Canada,
Belgium, England, Scotland, Sweden and Denmark.
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Study participants must experience CCS class III or IV
angina pectoris despite attempted optimal medical
therapy for 30 days prior to screening. Optimal medical
therapy includes beta-blockers, calcium-channel blockers
or long-action nitrates used at maximal tolerable doses
[15]. Only patients with limited coronary revascularization
options, either by PCI or CABG, are eligible to participate
in the study. The details related to the unsuitability for
revascularization are reviewed in details elsewhere [16].
Before randomization, participants undergo a history to
determine their CCS angina class, a physical examination,
a baseline SPECT stress test, and a dobutamine stress
echocardiogram. The day of the planned intervention, all
participants undergo a right heart cardiac catheterization
and a CS angiogram. Only candidates showing a mean
right atrial pressure ≤15 mmHg with CS anatomy suitable
for the Reducer implantation (nontortuous, nonaberrant,
CS diameter >9.5 mm but <13 mm) are eligible for
randomization.
The final protocol and amendments as well as the
consent form are reviewed and approved by the insti-
tutional review board and independent ethics commi-
ttee at each participating center. The study is being
conducted in compliance with the provisions of the
Declaration of Helsinki and relevant local country
regulations. All patients must provide written informed
consent.
Randomization and treatment protocol
Participants are randomized in a 1:1 ratio using a
centrally controlled computer-generated random alloca-
tion sequence. Treatment assignments are concealed in
numbered sealed envelopes. The allocation sequence
remains concealed until the study arm is assigned. Once
randomization is assigned, the participant is officially
enrolled in the study [17].
All participants remain blinded throughout the six-
month study period. While the interventional cardiolo-
gist implanting the Reducer is not blinded, the study
participants, the physician investigator responsible for
assessing the CCS angina class at follow-up, all core la-
boratories, the biostatisticians performing the analysis,
the members of the Clinical Event Committee (CEC), as
well as the members of the Data Safety Monitoring
Board (DSMB) are blinded to treatment assignment,
which will remain until study completion and until after
the database has been locked.
Coronary sinus reduction
All participants are pretreated with
3 80 mg aspirin daily
for at least 72 hours prior to the device implantation
Figure 1 The Neovasc Reducer
™ System. The Neovasc Reducer
™ System is comprised of the Neovasc Reducer
™ premounted on the Neovasc
Reducer
™ Balloon Catheter. (a) The Neovasc Reducer. (b) The Neovasc Reduce Balloon Catheter.
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days prior to the procedure or loading dose of 300 to
600 mg within 24 hours prior to the procedure) or
prasugrel (loading dose of 60 mg within 24 hours
prior to the procedure) continued for six months.
Participants randomized to the Reducer undergo sys-
temic anticoagulation with either an initial heparin bolus
(70 U/Kg) to reach and maintain an activated clotting
time above ≥200 seconds, or with bivalirudin (initial
bolus 0.75 mg/Kg, drip 1.75 mg/Kg/hr).
The methods of device implantation have been
described previously [13] using a percutaneous jugular
transvenous approach (Figure 2). Patients randomized to
the Reducer group have a Reducer implanted immedi-
ately following the CS angiography. Once the CS is
cannulated, a Reducer implantation takes approximately
15 minutes.
Participants assigned to the control group will undergo
a sham procedure, but with no additional invasive
manipulation than those required during the qualifying
right heart catheterization. The implanting physicians are
instructed to behave similarly during both Reducer and
sham implantations. Participants are offered headsets
playing music to mask the surrounding noise resulting
Table 1 Inclusion and exclusion criteria for COSIRA
A. Inclusion criteria B. Exclusion criteria
1. Patient >18 years of age Clinical
2. Symptomatic CAD with chronic refractory angina pectoris classified as
CCS class III or IV despite attempted optimal medical therapy for 30 days
prior to screening
1. Recent (<3 months) acute coronary syndrome
3. Patient has limited treatment options for revascularization by CABG or
PCI
2. Recent (<6 months) successful PCI or CABG
4. Evidence of reversible ischemia that is attributable to the left coronary
arterial system by dobutamine echocardiography
3. Recent (<1 month) unstable angina (recent onset, crescendo, or rest
angina with ECG changes)
5. Left ventricular ejection fraction >25% 4. De-compensated CHF or hospitalization due to CHF during the 3
months prior to screening
6. Male or nonpregnant female (NB: Females of child-bearing potential
must have a negative pregnancy test)
5. Patient with pacemaker or defibrillator electrode in the right atrium,
right ventricle, or coronary sinus
7. Patient understands the nature of the procedure and provides written
informed consent prior to enrollment
6. Life-threatening rhythm disorders or any rhythm disorders requiring an
internal defibrillator and or pacemaker
8. Patient is willing to comply with specified follow-up evaluation and
can be contacted by telephone
7. Severe COPD as indicated by a forced expiratory volume in one second
<55% of the predicted value
8. Patient cannot undergo exercise tolerance test (bicycle) for reasons
other than refractory angina
9. Severe valvular heart disease
10. Patient having undergone tricuspid valve replacement or repair
11. Chronic renal failure (serum creatinine >2 mg/dL), including patients
on chronic hemodyalisis
12. Moribund patients, or patients with comorbidities limiting life
expectancy <1 year
13. Contraindication to required study medications that cannot be
adequately controlled with premedication
14. Known allergy to stainless steel or nickel
15. Currently enrolled in another investigational device or drug trial that
has not completed the primary endpoint or that clinically interferes with
the current study endpoints
Anatomical
16. Mean right atrial pressure ≥_ 15 mmHg
17. Patient with anomalous or abnormal CS as demonstrated by
angiographic abnormalities defined either:
a. Abnormal CS anatomy (for example, tortuosity, aberrant branch,
persistent left SVC) and/or;
b. CS diameter at the site of planned Reducer implantation <9.5 mm or
>13 mm
CABG coronary artery bypass graft; CAD coronary artery disease; CCS Canadian Cardiovascular Society; CHF congestive heart failure; COPD chronic obstructive
pulmonary disease; CS coronary sinus; ECG electrocardiogram; PCI percutaneous coronary intervention; SVC superior vena cava.
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practice.
Outcomes
Primary and secondary endpoints of the COSIRA trial are
listed in Table 2. The primary end points will compare the
number of participants experiencing angina improvement
≥2 CCS grades six months after the intervention. To
maintain blinding, baseline and six-month CCS grading
are done by independent physicians unaware of the treat-
ment allocation. Questions to the patients about their
condition, with regards to CCS scoring, are scripted to en-
sure that every physician asks the same questions in an
identical manner to each patient.
After the procedure, participants are assessed at hospital
discharge, and post-procedurally at 30 days (office), three
months (office or telephone), and six months (office)
(Figure 3). At each of these follow-up visits, the occur-
rence of adverse events is evaluated. At the six-month
visit, an exercise tolerance test, a SPECT stress test, and a
dobutamine echocardiogram are performed. Following the
final safety and efficacy assessments, all participants
randomized to the Reducer undergo a CT angiogram to
assess CS patency. The schedule of procedures for the trial
is presented in Table 3.
A bicycle ergometry stress test adapted from the
Asymptomatic Cardiac Ischemia Pilot (ACIP) protocol
[18] was selected because the incremental increases in
exercise workload are more gradual (≤1.5 METS/stage)
compared to the larger work demands inherent in other
exercise testing protocols (for example, the Bruce proto-
col). In patients with advanced coronary artery disease,
this approach provides a greater discrimination in defin-
ing the time to onset of 1 mm ST-segment depression,
angina, and heart rate increase [19]. Exercise stress test
data as well as the dobutamine stress echocardiography
will be extracted and interpreted by an independent core
laboratory blinded to treatment assignment. Similarly,
data for the dobutamine stress echocardiography wall
motion score index (WMSI) will be extracted and
interpreted by an independent core laboratory blinded
to treatment assignment.
T h eS e a t t l eA n g i n aQ u e s t i o n n a i r e( S A Q )s c o r e[ 2 0 ] ,a
brief 19-item self-administered questionnaire that captures
five perspectives: physical limitation, anginal stability, an-
ginal frequency, treatment satisfaction, and disease percep-
tion will be used to assess quality of life.
The safety of the Reducer implantation will be monitored
by the procedural success, defined as successful delivery
and deployment to the intended site in the absence of an
adverse or serious adverse device-related event prior to
hospital discharge. Periprocedural serious adverse events
are defined as a composite of death, myocardial infarction,
cardiac tamponade, clinically driven redilation of a failed
Reducer, life-threatening arrhythmias (ventricular tachycar-
dia (VT) or ventricular fibrillation (VF)), and respiratory
failure through 30 days post-procedure, as adjudicated by
the CEC.
Figure 2 Delivery and implantation of the coronary sinus Reducer. Schematic representation of the delivery (a), dilation (b) and
implantation (c) of the Reducer in the coronary sinus. The Reducer has the appearance of an hourglass (arrowhead) once fully implanted (d).
Immediately after the implantation, the sinus remains patent and functional.
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will be performed at six months to document the pa-
tency of the device in the CS. To limit radiation expo-
sure, this test is only performed in patients assigned to
the Reducer and performed after the final CCS angina
class assessment has been fulfilled to maintain binding.
Cardiac magnetic resonance (CMR) mechanistic substudy
Patients enrolled in selected centers are offered participa-
tion in a CMR substudy primarily seeking to quantify the
variation in myocardial tissue oxygenation in response to
the CS Reducer implantation. Participants undergo a per-
fusion CMR at baseline and at six months following
randomization. Primary CMR measurements include the
stress-induced myocardial ischemic reactions, determined
by first-pass perfusion imaging after contrast injection,
and the blood oxygen level-dependent (BOLD) imaging.
BOLD CMR is a noncontrast technique that allows assess-
ment of myocardial oxygenation by utilizing the fact that
deoxygenated hemoglobin acts as a paramagnetic en-
dogenous contrast agent [21].
Samples size and power calculation
The study has been powered to detect a difference in the
proportion of patients improving ≥2 CCS angina classes
at six months after the implantation. The following
assumptions and hypotheses correspond to the primary
objective:
A = 15% of participants in the sham control group will
improve ≥2 CCS angina classes [22]
B = 40% of participants in the Reducer group will
improve ≥2 CCS angina classes [13,14]
Hypotheses:
H0:A=B
H1:A≠ B
Type I error rate = 5% (two-sided) with a Power = 80%
Drop out/lost to follow-up rate = 10%
Based on these assumptions, the sample size is 62 per
group, for a total trial size of 124. These hypotheses will
be tested with the Pearson chi-square test with continuity
correction. The statistical analysis of the primary endpoint
will be performed and presented following the intent-
to-treat (ITT) principle. A second set of analysis will be
performed using a per-protocol population, which will
include all enrolled patients who completed the procedure
and had a six-month CCS angina grade assessed. The
safety population will include all randomized patients
according to the actual treatment received. Patients who
Table 2 Outcomes of the PRIMACY trial
Primary endpoints 1. Proportion of patients experiencing an improvement of 2
or more CCS angina classes.
Secondary endpoints
The secondary endpoints will compare the variation of the change from baseline
to 6-month follow-up:
1. Wall motion score index by dobutamine stress
echocardiogram
2. Exercise treadmill test
a. The variation (change from baseline) in time to 1 mm
ST-segment depression (min);
b. Total exercise duration (min);
c. Maximal ST-segment depression (mm)
3. Proportion of patients experiencing an improvement
of ≥ _ 1 CCS angina classes
4. MACE - the composite of cardiac death, major stroke, and
myocardial infarction
5. The Seattle Angina Questionnaire scores, subdivided in
categories
a. physical limitation;
b. anginal stability;
c. anginal frequency;
d. treatment satisfaction, and
e. disease perception
6. Reduction in reversible perfusion defect by SPECT
7. Regional oxygenation improvement measured by BOLD
CMR (in selected centers only)
BOLD blood oxygen level-dependent; CCS Canadian Cardiovascular Society; CMR cardiac magnetic resonance; MACE major adverse cardiac event; min, minutes;
mm, millimeters; SPECT single-photon emission computed tomography.
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adjudicated by the CEC) before the six-month follow-up
visit will be counted as CCS angina improvement less than
two grades. A sensitivity analysis will be conducted to
assess the impact of patients lost on follow-up for reasons
other than cardiovascular death.
Statistical analysis
Whenever appropriate, the mean, standard deviation (SD),
median, interquartile range (IQR) will be presented for
continuous variables whereas the frequencies and percent-
age will be calculated for categorical variables. Descriptive
statistics X2a n dS t u d e n tt testing will be used to compare
b a s e l i n ea n dd e m o g r a p h i cc h a r acteristics between patients.
For both the dobutamine echocardiography WMSI and
the exercise stress test (time to 1 mm ST-segment depres-
sion), the analysis of covariance (ANCOVA) will be used
to compare the variation of the change from baseline to
six months between the Reducer and the sham-implanted
patients. In both cases, the baseline measurements will be
Figure 3 COSIRA study flow. AE, adverse event; CCS, Canadian Cardiovascular Society; CMR, cardiac magnetic resonance imaging; CT,
computerized tomography; ECG, electrocardiogram; ECHO, echocardiogram; ETT, exercise tolerance test; MIBI, sestamibi; RHC, right heart
catheterization; SAE, serious adverse event; SAQ, Seattle Angina Questionnaire; SPECT; single-photon emission computed tomography.
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are known to be non-normally distributed. If needed this
data will be transformed or analyzed with nonparametric
ANCOVA [24]. If appropriate, multivariable linear models
will be used to assess the association between independent
predictors and the continuous endpoints of the trial. The
survival free of major cardiac events (cardiac death, major
stroke, and myocardial infarction) will be displayed using
Kaplan-Meier curves. Depending on the number of events
recorded, multivariable Cox proportional hazards analysis
will be attempted.
Prespecified subgroups will examine the effect of
Reducer stratified according to: 1) the location of the
myocardial ischemia, including the right coronary artery
territory; 2) baseline left ventricular ejection fraction
(LVEF), and; 3) the total myocardial ischemia burden.
P values <0.05 will be considered statistically significant.
Given that COSIRA is a phase II study, no type I error ad-
justment for multiple comparisons will be incorporated.
All analyses will be performed using SAS version 9 or
greater (SAS Institute, Inc, Cary, NC, USA), unless other-
wise noted.
Safety and efficacy monitoring
An independent DSMB is chartered to monitor and
evaluate patient safety to identify any clinically relevant
trends, and to recommend whether the study should
continue. The first DSMB review to assess safety will
occur after approximately 30 randomized patients have
30-day data available. After approximately 50% of the
cohort has completed their six-month visit, the DSMB
will review safety and the results of an interim assess-
ment of the primary outcome. The results of the interim
efficacy assessment will be based on the Lan-DeMets
method using an O’Brien-Fleming sending function,
with one interim evaluation. At the time of the interim
assessment of the primary outcome, the DSMB will also
review the results from a conditional power analysis for
futility.
Discussion
The COSIRA trial will investigate whether the percu-
taneous reduction of the CS will reduce angina in
patients with refractory angina. By creating a controlled
local narrowing in the CS, the Reducer increases the
Table 3 Study procedures
Screening Procedure Discharge 30 Days 3 Months 6 Months
Procedure
Informed consent X
Medical history X
Physical exam X X X X
Listing of medication X X X X X
Pregnancy test X
1
Blood work X
1
Cardiac enzymes X
2 X
4
ECG X
2 XX X
CCS assessment X X X X
ETT X X
Dobutamine echo X X
Thallium/MIBI SPECT X X
SAQ X X X X
CMR X X
RH catheterization X
CS angiography X
Randomization X
Reducer implantation X
3
CT angiogram X
3
Adverse events X X X X X
Serious adverse events X X X X X
1Within seven days prior to procedure;
2within 24 hours prior to procedure;
3in Reducer group only, to be performed only after final assessments CCS angina class
and SAQ;
4cardiac enzymes (CK, CK-MB, and troponin) within 8 to 12 hours post-procedure. CCS Canadian Cardiovascular Society; CMR cardiac magnetic resonance
imaging; CS coronary sinus; CT computerized tomography; ECG electrocardiogram; ETT exercise tolerance test; MIBI sestamibi; RH right heart; SAQ Seattle Angina
Questionnaire; SPECT single-photon emission computed tomography.
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balance the regional capillary pressure, decrease resist-
ance in the subendocardial capillaries, and favor a re-
distribution of oxygenated coronary blood toward the
underperfused subendocardium. The coronary sinus
Reducer potentially represents a new percutaneous
treatment option for a growing population of patients
with limited revascularization options and persistent
angina symptoms.
The Reducer is a permanently implanted device with
theoretical risks and inconvenience. The Reducer could
lead to a CS thrombosis. However, data from the cardiac
resynchronization therapy seem to suggest that foreign
objects (such as leads) inserted in the CS rarely lead to
thrombosis. When such thromboses do occur, their
course is unpredictable and often clinically silent. The
duplicity of collateral circulation between the great
cardiac veins and the Thebesian veins can prevent myo-
cardial injury [25]. In patients with an insufficient col-
lateral network or with a variant anatomy, an acute
coronary sinus thrombosis could be potentially fatal.
Cases of venous hemorrhagic myocardial infarction
have been reported, along with pericardial tamponade
and sudden cardiac death [26]. In the COSIRA trial,
acute Reducer thromboses are prevented by minimizing
endothelial injury with the customized delivery catheter.
While not proven efficient in venous circulation, dual
antiplatelet therapy for a minimum of six months is also
administered. In the eventuality of a Reducer thrombosis,
thrombectomy can be performed [27] and if needed the
narrowed hourglass neck of the Reducer can be completely
expanded by angioplasty to allow an unrestricted passage
of venous blood. The long-term consequences of myocar-
dial venous hypertension remain largely unknown. We an-
ticipate that six months should be enough to detect the
adverse consequences of myocardial venous hypertension
that could result from the Reducer implantation. Potential
adverse consequences such as diastolic dysfunction or car-
diac fibrosis should be picked up by the echocardiographic
and cardiac resonance imaging follow-up. Of note, no such
adverse consequences could be observed in the phase I
patients followed up for more than three years [14].
T h eC O S I R At r i a li sap h a s eI It r i a la n ds e v e r a l
limitations inherent in this type of study must be
discussed. The COSIRA trial was primarily designed to
test whether the Reducer can improve symptoms of re-
fractory angina. The relatively small sample size of
COSIRA will not answer the clinical benefit associated
with the Reducer based upon hard cardiovascular
events. Still, development programs for devices to treat
chronic symptomatic conditions do not have to un-
equivocally demonstrate a net clinical benefit on hard
endpoints such as mortality or myocardial infarction
[28]. However, we are confident that the COSIRA trial
will provide the required amount of information to
gauge the level of risk with respect to the anticipated
symptomatic relief gained with the device. Ultimately,
the information will be used to help design future
clinical investigations.
Wefeelthatpatient-reportedangina(CCS)complemented
by the patient-centered SAQ, is the most appropriate
endpoint in a phase II trial. However, angina is subject to a
placebo effect, and biased by several factors despite blinding.
Traditionally, time to 1 mm ST-segment deviation and other
stress test outcomes are regarded by regulatory agencies as
the most appropriate endpoints to approve new therapies.
Consequently, many angina trials have used an exercise
treadmill test or bicycle ergometer outcomes as primary
endpoints. A large proportion of patients with advanced
CAD(suchasthosetargetedintheCOSIRAtrial)areunable
to exercise appropriately. Consequently, efficacy conclusions
drawn from a trial using stress test outcomes may have been
poorly generalizable to a large contingent of patients who
may potentially benefit from this therapy. Likewise, it would
have been challenging to reach a statistically sound conclu-
sion with the intended sample size for COSIRA given the
important coefficient of variations typically observed with
stress test measurements. For this reason, time to 1 mm
ST-segment deviation will be monitored in the COSIRA trial
but will not be used as a formal inclusion criterion. Finally,
the Reducer may not address myocardial ischemia resulting
from right coronary artery disease, since the territory is
usually not drained by the CS. Information collected during
the COSIRAtrial shouldhelpanswerthis question.
Trial status
At the time of manuscript submission, 70 patients have
been enrolled in the trial, of which 45 have completed the
six-month follow-up.
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